Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Q1 Performance update

26 Jul 2017 07:00

RNS Number : 0791M
3i Group PLC
26 July 2017
 

26 July 2017

 

3i Group plc

FY2018 Q1 performance update

 

A busy start to the year with four new Private Equity investments and good portfolio performance

 

· NAV per share of 628 pence and total return of 4.1% at 30 June 2017

 

· Good level of new investment in Private Equity with £276 million invested in Hans Anders and Lampenwelt in the quarter and a further £241 million committed to Formel D and Cirtec

 

· Successful close of two new Infrastructure funds, the 3i Managed Infrastructure Acquisitions Fund and the 3i European Operational Projects Fund

 

 

Simon Borrows, Chief Executive, commented:

 

"This was another good quarter for 3i and our portfolio of international investments is performing well against an improving economic backdrop. We completed or signed four new investments in Germany, the Netherlands and the US and some £250 million of divestments, including the announced sale of Mémora at a significant uplift to its March 2017 value. We also added two new Infrastructure funds, the 3i Managed Infrastructure Acquisitions Fund and the 3i European Operational Projects Fund."

 

 

Private Equity

 

Portfolio performance

The Private Equity portfolio performed well in the quarter. Action continued to see strong earnings growth and cash flow generation. There was robust earnings growth across the portfolio more generally with a good contribution from ATESTEO, Q Holding and Audley Travel, together with strong cash flow generation from Scandlines.

 

Private Equity investments

We completed our investments in Hans Anders (£172 million) and Lampenwelt (£104 million) in May 2017 and Formel D (£136 million) in July 2017. We also announced a c.$136 million investment in Cirtec Medical, a leading provider of outsourced engineering and manufacturing to the medical device sector, which is expected to complete by 30 September 2017.

 

Private Equity realisations

We generated total cash proceeds of £107 million in the quarter from the full realisations of MKM and Dphone at uplifts of 3% and 30% respectively against 31 March 2017 book value.

 

 Realisation proceeds

£m

Full realisations

MKM

70

Dphone

26

Other

11

Total Q1 FY2018 cash proceeds

107

 

We also announced the sale of Mémora on 17 July 2017. This disposal, which is expected to complete by the end of September 2017, will generate proceeds of c.£117 million to 3i. Mémora was valued at £86 million at 31 March 2017 and has been moved to an imminent sales basis at 30 June 2017.

 

 

Infrastructure

 

Our team, which advises 3i Infrastructure plc, is working actively on its more recent acquisitions, including potential follow on investments, and its pipeline of possible new investments. 3i also invested £21 million in the new 3i Managed Infrastructure Acquisitions Fund and committed €40 million to the new 3i European Operational Projects Fund, which achieved its first close in April 2017.

 

 

Top 10 investments by value at 30 June 2017

 

Valuation

Valuation

Valuation

Valuation

Mar-17

Jun-17

basis

currency

£m

£m

Activity in the quarter

Action

Earnings

EUR

1,708

1,835

3i Infrastructure plc

Quoted

GBP

655

658

Ex-dividend date 15 June 2017

Scandlines

DCF

EUR

538

571

Q Holding

Earnings

USD

222

238

Weener Plastic

Earnings

EUR

200

213

Audley Travel

Earnings

GBP

185

194

Basic-Fit

Quoted

EUR

184

182

Hans Anders

Earnings

EUR

-

175

New investment

ATESTEO

Earnings

EUR

160

172

BoConcept

Earnings

DKK

146

156

 

The top 10 investments in this table comprise 71% (31 March 2017: 70%) of the total Proprietary Capital portfolio by value.

 

 

Total return and NAV position

 

The continued weakening of sterling against the euro following the UK General Election in June 2017 contributed to a total foreign exchange gain in the quarter of £68 million. Based on the balance sheet at 30 June 2017, a 1% movement in the euro and US dollar would result in a total return movement of £37 million and £7 million respectively. Altogether the diluted NAV per share increased to 628 pence (31 March 2017: 604 pence) and 609.5 pence following the payment of the FY2017 final dividend.

 

 

Balance sheet and dividend

 

The Group's balance sheet remains well funded. Net cash reduced to £161 million, due to the investment activity in the quarter. Liquidity remained strong at £1,086 million. The £136 million investment in Formel D completed on 17 July 2017 and the 18.5 pence FY2017 final dividend (£178 million) was paid on 21 July 2017.

 

 

Notes

 

1.

Balance sheet values are stated net of foreign exchange translation. Where applicable, the GBP equivalents at 30 June 2017 in this update have been calculated at a currency exchange rate of 1.1388:£1 and $1.2989:£1 respectively. At 30 June 2017, 61% of the Group's net assets were in euro and 12% were in US dollar.

2.

At 30 June 2017 3i had 968.4 million diluted shares.

3.

Action was valued using a post discount run-rate EBITDA multiple of 16.0x based on its run-rate earnings to 19 June 2017, the closest period end to 3i's.

 

 

- ENDS -

 

 

For further information, please contact:

Silvia SantoroInvestor Relations DirectorTel: 020 7975 3258

Kathryn van der Kroft

Communications DirectorTel: 020 7975 3021

 

 

About 3i Group

 

3i is a leading international investment manager focused on mid-market Private Equity and Infrastructure. Our core investment markets are northern Europe and North America. For further information, please visit: www.3i.com

 

All statements in this performance update relate to the three month period ended 30 June 2017 unless otherwise stated. The financial information is unaudited and is presented on 3i's non-GAAP Investment basis in order to provide users with the most appropriate description of the drivers of 3i's performance. Net asset value ("NAV") and total return are the same on the Investment basis and on an IFRS basis. Details of the differences between 3i's consolidated financial statements prepared on an IFRS basis and under the Investment basis are provided in the 2017 Annual report and accounts. There have been no material changes to the financial position of 3i from the end of this quarter to the date of this announcement.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSELFWIFWSESW
Date   Source Headline
1st Feb 20187:00 amRNSFY2018 Q3 performance update
31st Jan 20184:17 pmRNSTotal Voting Rights
31st Jan 20184:16 pmRNSDirector/PDMR Shareholding
2nd Jan 20184:15 pmRNSPortfolio Update
19th Dec 20173:18 pmRNSTotal Voting Rights
19th Dec 20173:15 pmRNSDirector/PDMR Shareholding
12th Dec 20173:05 pmRNSBlock listing Interim Review
6th Dec 201711:13 amRNSDirector/PDMR Shareholding
5th Dec 201712:00 pmRNSDirector/PDMR Shareholding
4th Dec 201710:32 amRNSDirector Declaration
30th Nov 20173:29 pmRNSTotal Voting Rights
30th Nov 20173:28 pmRNSDirector/PDMR Shareholding
16th Nov 201712:19 pmRNSDoc re. Half Yearly Report 2017
16th Nov 20177:00 amRNS3i Group Half-year results to 30 September 2017
31st Oct 20173:54 pmRNSDirector/PDMR Shareholding
31st Oct 20173:53 pmRNSTotal Voting Rights
3rd Oct 201712:37 pmRNSPortfolio Update
29th Sep 20173:51 pmRNSTotal Voting Rights
29th Sep 20173:50 pmRNSDirector/PDMR Shareholding
18th Sep 20178:30 amRNSPrivate Equity Capital Markets Seminar
31st Aug 20173:48 pmRNSTotal Voting Rights
31st Aug 20173:46 pmRNSDirector/PDMR Shareholding
31st Jul 20174:41 pmRNSTotal Voting Rights
31st Jul 20174:36 pmRNSDirector/PDMR Shareholding
28th Jul 20174:12 pmRNSDirector/PDMR Shareholding
26th Jul 20173:14 pmRNSDirector/PDMR Shareholding
26th Jul 20177:00 amRNSQ1 Performance update
6th Jul 20173:24 pmRNSPortfolio Update
30th Jun 20174:28 pmRNSDirector/PDMR Shareholding
30th Jun 20173:18 pmRNSTotal Voting Rights
30th Jun 20173:17 pmRNSDirector/PDMR Shareholding
29th Jun 20172:54 pmRNSResult of AGM
29th Jun 20172:35 pmRNSDoc re. AGM Resolutions
29th Jun 20172:25 pmRNSDirector/PDMR Shareholding
19th Jun 20174:19 pmRNSDTR 6.3.5
13th Jun 201711:26 amRNSDirector/PDMR Shareholding
12th Jun 20174:48 pmRNSBlock listing Interim Review
2nd Jun 201711:16 amRNSDirector/PDMR Shareholding
31st May 20174:25 pmRNSTotal Voting Rights
31st May 20174:21 pmRNSDirector/PDMR Shareholding
31st May 201710:12 amRNSDoc re. 2017 Annual Report and Accounts
30th May 20178:30 amRNSPrivate Equity Capital Markets Seminar
18th May 20172:49 pmRNSDirector/PDMR Shareholding
18th May 20179:41 amRNSDirector/PDMR Shareholding
18th May 20177:00 amRNSResults for the year to 31 March 2017
28th Apr 20173:05 pmRNSTotal Voting Rights
28th Apr 20173:05 pmRNSDirector/PDMR Shareholding
6th Apr 201711:37 amRNSPortfolio Update
6th Apr 201710:47 amRNSDirector Declaration
31st Mar 20171:50 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.